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1. Introduction 
1.1 Dementia with Lewy bodies: An overview 
Dementia with Lewy bodies (DLB) is a progressive neurodegenerative disorder 
characterized by the core clinical features of fluctuating consciousness, visual hallucinations 
and parkinsonism.  
The term DLB and the clinical criteria were first introduced and proposed by Mc Keith and 
colleagues in 1996 during the First International Workshop of the Consortium on Dementia 
with Lewy Bodies (McKeith et al., 1996) and were revised in 2005 to improve the sensitivity 
for diagnosis (McKeith et al., 2005). Interestingly, in these revised criteria, imaging with 
Single Photon Emission Computed Tomography (SPECT) or Positron Emission 
Tomography (PET) played an important role for the first time in the clinical diagnostic 
criteria of a dementia and was included as a suggestive feature supporting the diagnosis.  
After Alzheimer's disease (AD), DLB is now considered the second most common type of 
degenerative dementia in elderly people (Aarsland et al., 2008; McKeith et al., 2004) 
observed in 15 to 25% of autopsy series (Heidebrink, 2002; McKeith et al., 1996; Perry et al., 
1990). These percentages are consistent with the few available epidemiological population-
based studies (de Silva et al., 2003; Herrera et al., 2002; Rahkonen et al., 2003; Stevens et al., 
2002; Yamada et al., 2001; Yamada et al., 2002), which have reported the prevalence of DLB 
ranging from 0 to 30.5% of all dementia cases in individuals older than 65 years and from 0 
to 5% in the general population (Zaccai et al., 2005). However, DLB is a regularly 
misdiagnosed clinical condition, with autopsy reports indicating a higher frequency than 
that detected in clinical settings (Farina et al., 2009; Mollenhauer et al., 2010).  
The pathological background of DLB has been a matter of controversy and is a complex 
issue (see Fig. 1). The core neuropathological finding is the presence of α-synuclein 
aggregates which form neuronal inclusions called Lewy bodies (LBs). According to the 
consensus pathological guidelines, based on a semiquantitative scoring of α-synuclein 
pathology (LBs density and distribution) in specific brain regions, DLB is distinguished into 
three different phenotypes (brainstem, transitional/limbic, and diffuse neocortical). 
Moreover, DLB pathological features are often associated to various degrees of AD 
pathology (i.e. limbic and neocortical spread of LB lesions with or without concomitant AD 
amyloid plaque pathology). 
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Fig. 1. Clinicopathological interaction between dementia with Lewy bodies (DLB), 
Parkinson's disease dementia (PDD) and Alzheimer's disease (AD). LBs: Lewy Bodies; 
NFTs: neurofibrillary tangles;  APs: amyloid plaques. 
As previously described, the clinical criteria for the diagnosis of DLB were established in 
1996 (McKeith et al., 1996) and revised in 2005 (McKetih et al., 2005) to include additional 
suggestive clinical features (REM sleep behaviour disorder and  severe neuroleptic 
sensitivity) as well as specific neuroradiological findings (Dopamine SPECT or PET 
imaging). The central feature for the diagnosis, that must be present for either probable or 
possible DLB, is a condition of dementia. This dementia is defined as a progressive cognitive 
decline of sufficient magnitude to interfere with normal social or occupational function and 
with prominent deficits on tests of attention, executive function, and visuospatial ability. 
The cognitive deficits are not necessarily associated with memory impairment at list at the 
early stages of the diseases. Then, “probable” DLB is characterized by the presence of this 
central characteristic with any two of the three core features (fluctuating cognition, recurrent 
visual hallucinations, or parkinsonism) or one core feature and one suggestive feature, 
whereas “possible” DLB is diagnosed in the absence of any core features but in the presence 
of one or more suggestive features. Finally, clinical criteria also includes supportive features 
(commonly present but not proven to have diagnostic specificity) and  findings that do not 
support DLB (see Table 1 for a detailed description of clinical criteria).  
DLB shares many common clinical (motor, cognitive, attentional, and psychiatric 
symptoms), neuropsychological (prominent deficits on tests of attention, executive function, 
and visuospatial ability) and pathological features (LBs α-synuclein aggregates) with 
Parkinson Disease Dementia (PDD). In the last years, in fact, DLB and PDD have been both 
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THE CLINICAL DIAGNOSTIC CRITERIA FOR DEMENTIA WITH LEWY BODIES 
from the Third International report of the DLB consortium  
(McKeith et al, 2005) 
CENTRAL FEATURE 
 Dementia with impairment in 
everyday functioning. 
 Prominent or persistent memory 
impairment may not necessarily 
occur in the early stages but is 
usually evident with progression. 
 Deficits on tests of attention, 
executive function, and 
visuospatial ability may be 
especially prominent. 
CORE FEATURES 
 Fluctuating cognition 
with pronounced 
variations in attention and 
alertness 




 REM sleep behavior 
disorder 
 Severe neuroleptic 
sensitivity 
  Reduced dopaminergic 
activity in basal ganglia 
(SPECT or PET imaging) 
For a diagnosis of "Probable" DLB: 
Central feature  AND two core features  - OR -Central feature  AND one or more core features with 
one or more suggestive features  
For a diagnosis of "Possible" DLB: 
Central feature AND one core feature  - OR - Central feature AND one or more suggestive features 
-- 
Timing cut-off 
"one -year rule" between the onset of dementia and parkinsonism to distinguish DLB and PDD  
SUPPORTIVE FEATURES  
these are often present but do not have diagnostic specificity 
 Repeated falls and syncope 
 Transient, unexplained loss of consciousness 
 Severe autonomic dysfunction, e.g., orthostatic hypotension, urinary incontinence 
 Hallucinations in other modalities 
 Systematized delusions 
 Depression 
 Relative preservation of medial temporal lobe structures on CT/MRI scan 
 Generalized low uptake on SPECT/PET perfusion scan with reduced occipital activity 
 Abnormal (low uptake) MIBG myocardial scintigraphy 
 Prominent slow wave activity on EEG with temporal lobe transient sharp waves 
FINDINGS THAT DO NOT SUPPORT DLB 
 Presence of cerebrovascular lesions on brain imaging (brain CT or MRI) or focal 
neurologic signs  
 Presence of any other physical illness or brain disorder sufficient to explain the clinical 
symptoms 
 Parkinsonism that occurs for the first time when dementia is severe 
Table 1. The clinical diagnostic criteria for dementia with Lewy bodies taken from the third 
international report of the DLB consortium (McKeith et al., 2005). SPECT:  single photon 
emission computed tomography; PET: positron emission tomography; CT: computed 
tomography; MRI: magnetic resonance imaging; MIBG: 31-iodine metaiodobenzylguanidine 
single photon emission computed tomography; EEG: electroencephalography. 
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(Lippa et al., 2007). PDD should be the suspected diagnosis in patients with Parkinson’s 
disease (PD) who develop cognitive deficits and/or behavioural disturbances such as 
hallucinations during the course of their illness (Emre et al., 2007). These two diseases are so 
closely related that they are distinguished by an arbitrary cut-off ("one year rule") in the 
timing of motor compared to cognitive dimensions (PDD can be diagnosed only when 
cognitive deterioration supervenes after one year of the motor symptoms onset). Their 
response to the treatment with acetylcholinesterase inhibitors (AChEI) and the side effects 
associated with administration of conventional neuroleptic drugs are similar. Whether the 
distinction between PDD and DLB is nowadays based on an arbitrary time criterion, the 
distinction between DLB and other types of dementias such as Alzheimer Disease (AD) at 
the onset (Watson et al., 2009) is not always straightforward. Particularly, clinical 
differentiation between DLB and AD is sometimes difficult in the early stage because the 
symptoms overlap and the cognitive decline can also appear without the parkinsonism. In 
case of clinical uncertainty some additional investigation for differential diagnosis can be 
helpful: neuropsychological evaluation with formal tests, neuroimaging tools such as 
magnetic resonance imaging (MRI) or nuclear medical procedures (PET/SPECT), 
electroencephalography (EEG) and cerebrospinal fluid analysis. 
2. Neuroimaging techniques contribution to DLB diagnosis 
In this chapter we propose a systematic literature review concerning the principal 
neuroimaging techniques used for the diagnosis of DLB and their results. In contrast to PET 
and SPECT analysis, MRI represents a non-invasive tool to assess changes in macroscopic 
tissue structure (conventional MRI), microstructure (diffusion tensor imaging, DTI), 
metabolism (MR Spectroscopy, MRS), and cerebral activity (functional MRI, fMRI), and 
could bring invaluable additional information for the diagnosis of the pathology. The 
systematic literature search was performed using the computer database MEDLINE 
accessed via the Web of Knowledge. Two searches were performed including the following 
terms: "radionuclide imaging"[MeSH Terms] AND "lewy body disease"[MeSH Terms] for 
the first and "magnetic resonance imaging"[MeSH Terms] AND "lewy body disease"[MeSH 
Terms] for the second search. We limited the results with these criteria: Humans studies, 
English language, and publication date of last five years (from 2005/01/01 to 2011/03/01). 
The period was limited to the last five years in order to include works published after the 
revision of the clinical criteria for DLB (McKeith et al., 2005). This search produced a total of 
165 papers, which were screened individually by title and abstract, looking for information 
pertaining to PET/SPECT and MR studies in DLB. Moreover, the bibliographies of relevant 
papers were hand searched to find additional references. In this way,  84 original research 
papers were identified. 
2.1 Functional nuclear imaging techniques to diagnose DLB 
The above mentioned techniques PET and SPECT represent well-established, reliable 
imaging methods to assess the functional and metabolic brain changes in DLB (McKeith et 
al., 2005; McKeith et al., 2007). In Box A, technical aspects of these techniques are briefly 
summarized. The role of these techniques is well defined in the context of DLB (McKeith et 
al., 2007), although these procedures are very expensive and not widely used in common 
radiological settings. Moreover, the need of radioactive isotope injection limits the 
application of these exams only to cases of uncertain or difficult diagnosis. 
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2.1.1 Single Photon Emission Computed Tomography (SPECT)  
SPECT studies on DLB have been mainly addressed to the investigation of: 1) efficiency of 
dopamine transporter (DAT) in the the nigrostriatal pathway (usually referred to as DAT 
imaging); 2) the characteristics of perfusion within brain compartments. 
Box A: Functional Nuclear Imaging Techniques: PET and SPECT
Positron Emission Tomography (PET) and  Single Photon Emission Computed 
Tomography (SPECT) are highly specialized nuclear imaging techniques which provide 
a means to quantitatively study the metabolic processes within the body and reliably 
reveal functional abnormalities in the presence of various diseases.  
PET acquisitions require firstly the injection of a short-lived radioactive isotope, which 
combines itself with a specific biologic molecule present in the body. This procedure 
permits to observe the concentration of that molecule in different structures. After a 
determined period of time, the isotope decays with the emission of a positron which 
immediately annihilates with an electron, producing a pair of gamma rays in opposite 
directions. Particular rings of detectors containing special crystals that produce light 
when hit by a gamma ray are included within the PET scanner, and the scanner's 
electronics record these detected gamma rays during the acquisition and map an image 
of the area where the radiopharmaceutical is located. This process allows the 
observation of the metabolic activity of the biologic molecule combined with the 
radiopharmaceutical. For example, glucose combined with a radioisotope will show the 
pathway followed by glucose in the brain, in the heart, or in a growing tumour.   
SPECT procedure of image acquisition is similar to PET, but simpler, as particular 
radiopharmaceuticals are employed, which directly emit gamma rays during their 
decay. Larger detectors of gamma rays rotate around the patient. 
In this way, nuclear medicine techniques of neuroimaging are able to measure the 
physiological functioning of the brain, and can be useful to diagnose a multitude of 
medical conditions, e.g. heart disease, infection, the spread of cancer, thyroid disease, 
but also stroke, head trauma, dementia. The results of the analysis are spatial colour 
maps of the radioactivity distribution within tissues and with these images it could be 
shown that maps of activated brain regions could be produced by detecting the indirect 
effects of neural activity on variables such as Cerebral Blood Flux (Fox et al., 1986), 
Cerebral Blood Volume (Fox and Raichle, 1985) and blood oxygenation (Fox and 
Raichle, 1985; Frostig et al., 1990). Thanks to the double photon emission in PET, the 
acquisition with PET generates results faster and therefore limits radiation exposure to 
the patient. The amount of radiation exposure the patient receives in PET is about the 
same as two chest X-rays.  
In respect to fMRI, PET requires multiple acquisitions and the combination of multiple 
individual brain images in order to obtain a reliable signal. This results in an extension 
of the acquisition time.  
Furthermore, PET and SPECT do not provide structural information about the inspected 
tissues, therefore the acquisition of images using other imaging techniques such as 
structural MRI is needed, to precisely localize the resulting activations. Alternatively, in 
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DAT SPECT is useful in DLB for the investigation of dopaminergic neurons in basal ganglia 
(caudatum and putamen), as previous literature proved that a loss of dopaminergic 
neurostriatal neurons is detectable in DLB but not in AD (Piggott et al., 1999; Suzuki et al., 
2002). The first ligand used in dopaminergic SPECT was [123I]-2b-carbomethoxy-3b-(4-
iodophenyl) tropane (b-CIT). More recently, the ligand [123I] N-x-flouropropyl-2b-
carbomethoxy-3b-(4-iodophenyl) nortropane (FP-CIT) was introduced, requiring a shorter 
time interval between injection and scanning (R. W. H. Walker and Z. Walker, 2009). SPECT 
with this ligand (FP-CIT SPECT) has been included in the last revision of the International 
Consensus Criteria for DLB (McKeith et al., 2005). In particular, in a phase III multicentre 
study among a large cohort of subjects,  McKeith and co-workers (McKeith et al., 2007) 
determined the effectiveness of FP-CIT SPECT to distinguish DLB from other dementias 
(principally AD), revealing a sensitivity and specificity of respectively 78% and 90% 
respectively. So far, there have been published many studies that investigated DLB by 
dopaminergic SPECT (Colloby et al., 2005; David et al., 2008; Lim et al., 2009; O’brien et al., 
2009; Roselli et al., 2009;  Walker et al., 2007). All these works consistently show the 
diagnostic value of dopaminergic SPECT as applied to DLB, through the evaluation of the 
striatal dopaminergic innervations reduction,  also in the distinction from other dementias 
(Soret et al., 2006). In particular, Lim and colleagues (Lim et al., 2009) compared b-CIT 
SPECT with FDG-PET in the investigation of patients with DLB and AD, concluding that 
SPECT shows higher accuracy than PET in improving the diagnostic confidence of DLB. 
Moreover, Roselli et al. (Roselli et al., 2009) found significant correlations between decreased 
striatal DAT levels and visual hallucinations in DLB patients. The association of behavioural 
disturbances and SPECT analysis was also investigated (David et al., 2008), in order to 
assess the relationship between apathy and DAT uptake in DLB and AD patients: a 
significant correlation was found between lack of initiative and bilateral putamen DAT 
uptake, demonstrating a relationship between apathy and DAT levels. 
Perfusion SPECT studies, instead, use markers such as 99mTc- hexamethylpropyleneamine 
oxime to identify deficits in the functional pattern of brain activity. The majority of available 
studies highlighted a characteristic pattern of hypoperfusion in DLB patients in parietal and 
occipital brain areas (Brockhuis et al., 2006; Hanyu et al., 2006a; Lobotesis et al., 2001). 
However, other studies also suggested the presence of hypoperfusion in the  frontal, 
parietal, and temporal cortex and in the thalamus (Chang et al., 2008). The differentiation 
between AD and DLB patients was often investigated by means of this second perfusion-
based SPECT approach, in order to identify characteristic features allowing to distinguish 
between the two most common types of dementias (Colloby et al., 2010a; Colloby et al., 
2010b;  Goto et al., 2010; Kasama et al., 2005; Kemp et al., 2005; Mito et al., 2005; Shimizu et 
al., 2005; Shimizu et al., 2008; Tateno et al., 2008a). When compared with AD, DLB patients 
presented a preserved perfusion in the medial temporal lobe structures and a hypoperfusion 
in the occipital lobes, besides an increased perfusion in the striatum and thalamus 
bilaterally. In a recent study by Colloby and colleagues (Colloby et al., 2010a), the utility of 
99mTc-exametazime SPECT in the distinction between AD and DLB was verified through a 
Region Of Interest (ROI) approach and the Principal Component Analysis (PCA). The ROI 
analysis showed decreased regional CBF in AD compared to DLB, in the medial temporal 
lobe, in the striatum bilaterally and in the right thalamus. 
Moreover, a distinction between the two groups was possible through the analysis of the 
principal components (PCs). Two components, in fact, were identified as being differentially 
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affected in AD and DLB. The former revealed concomitant decreased perfusion in the 
medial temporal lobes and increased perfusion in the cerebellum of AD compared to DLB 
patients. Conversely,  the latter represented a concomitant increase of regional CBF in 
thalamus bilaterally ,and in the right striatum of DLB compared to AD patients.  
Interestingly, SPECT imaging was also used in combination with other measures to better 
detect changes in DLB. Several studies (Hanyu et al., 2006b;  Inui et al., 2007; Novellino et 
al., 2010; Tateno et al., 2008b) which combined SPECT and (1,2,3)I-metaiodobenzylguanidine 
myocardial (MIBG) scintigraphy reported that the accuracy power in the diagnostic process 
of DLB resulted increased. Furthermore, Goto and colleagues (Goto et al., 2010) proposed to 
combine the computation of ratios on perfusion SPECT with MRI volumetric data 
(hippocampal, occipital, and striatal structures) to discriminate between DLB and AD. They 
found that the striatal volume and the occipital SPECT ratio in the DLB group was lower 
than that in the AD group and concluded that the combination of SPECT and MRI might 
contribute to a successful differential diagnosis of DLB. Chang et al. (Chang et al., 2008), 
instead, demonstrated the efficacy of perfusion SPECT combined with neuropsychological 
evaluation to differentiate early stage DLB patients at early clinical stage from those 
suffering from PD. SPECT images analysed with a ROI approach resulted in a pattern of 
significant hypoperfusion in DLB compared with healthy controls in frontal, parietal, 
thalamic, and temporal areas; consistent to this imaging finding, neuropsychological tests 
revealed the presence of deficits in DLB patients with respect to controls including the 
following cognitive domains: mental manipulation, short-term memory, abstract thinking, 
drawing and semantic verbal fluencies. Compared with PD, DLB patients showed 
significantly reduced SPECT signals in temporal areas and had lower scores at 
neuropsychological evaluation for mental manipulation, drawing and semantic verbal 
fluency. Conversely, SPECT analyses (FP-CIT and DAT) were unable to discriminate DLB 
and PDD (Rossi et al., 2009), thus supporting the hypothesis that these two forms of 
dementia belong to a continuum spectrum of a unique disease. 
In conclusion, the two different SPECT analyses (DAT and perfusion) have proven to be 
both useful, but DAT scan seems to be more robust and accurate for diagnostic purposes, as 
described in a recent study by Colloby and colleagues (Colloby et al., 2008).  These authors 
directly compared the performances of the two SPECT approaches when applied to the 
differential diagnosis between AD and DLB, and identified dopaminergic SPECT as the 
technique with higher diagnostic accuracy (ROC curve area 0.83, sensitivity 78.6%, 
specificity 87.9% in respect to perfusion SPECT with ROC curve area 0.64, sensitivity 64.3%, 
specificity 63.6%).  
2.1.2 Positron Emission Tomography (PET) 
Together with SPECT, PET allows the functional investigation of brain activity and 
metabolism (see Box A) and therefore represents a powerful instrument for the early 
detection of dementia (Koeppe et al., 2005), since it was proven that brain function deficit in 
dementia occurs long before disease clinical evidences (Tartaglia et al., 2011).   The use of 
different radioisotopes increases PET versatilities. Depending on the specific tracer used, in 
fact, PET imaging allows the representation of specific molecules, and therefore the analysis 
of different functioning systems (e.g. the neural energy metabolism with F-18 2-fluoro-2-
deoxy-D-glucose; the cholinergic way with N-11C-methyl-4-piperidyl acetate; the 
dopaminergic with 18fluorodopa; the brain amyloid burden with  Pittsburgh compound B).   
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The more common tracer used in PET clinical studies is the F-18 2-fluoro-2-deoxy-D-glucose 
(FDG), which provides information about neuronal energy metabolism, in terms of regional 
glucose uptake. In the context of DLB, previous FDG-PET studies revealed a pattern of 
hypometabolism in the medial occipital cortex (Klein et al., 2010; Perneczky et al., 2008a; 
Satoh et al., 2010), in agreement with the previously reported SPECT data of hypoperfusion. 
Furthermore, other literature data found a correlation between cerebral hypometabolism in 
right temporoparietal cortex, prefrontal cortex and the precuneus and patients’ performance 
level of everyday competence (Perneczky et al., 2008b; Perneczky et al., 2009a). Moreover, a 
recent study by Miyazawa and co-workers (Miyazawa et al., 2010) introduced a new pattern 
of hypermetabolism in DLB regarding three different areas: the peri-motor area, the basal 
ganglia and the cerebellum. Interestingly, only patients with hypermetabolism in all these 
three areas experimented recurrent visual hallucinations, therefore authors concluded that 
this pattern may be related to the core features of this behavioural disturbance.   
In recent years, these relationships between brain perfusion and symptoms domain were well 
investigated (Fujishiro et al., 2010; Miyazawa et al., 2010; Nagahama et al., 2008; Nagahama et 
al., 2010; O’Brien et al., 2005; O’Brien et al., 2008; Perneczky et al., 2010). The cognitive 
performances on visual spatial and attentional tasks in DLB were proved to be closely related 
to the frontal-subcortical network dysfunction of these patients (Nagahama et al., 2008; 
Perneczky et al., 2008a; Perneczky et al., 2009b; Perneczky et al., 2010). A recent FDG-PET 
study by Fujishiro and colleagues (Fujishiro et al., 2010) demonstrated the correlation between 
REM sleep behaviour disorder and the development of DLB, observing that the typical pattern 
of occipital hypometabolism  on FDG-PET clearly manifested in patient with DLB also in 
prodromal stages. Furthermore, distinguishable cerebral networks were associated with 
different psychotic symptoms in DLB patients: dysfunctions of the parietal-occipital 
association cortices with visual hallucinations; dysfunctions of limbic and paralimbic 
structures with misidentification and relative hyperperfusion in the frontal cortex with 
delusions (Nagahama et al., 2010; Perneczky et al., 2008a; Perneczky et al., 2009b). 
As to the comparison with PD, instead, a metabolic decrease was found in DLB in the 
inferior and medial frontal lobes and in the right parietal lobe (Yong et al., 2007). Moreover, 
a comparison with PDD revealed similar pattern of metabolism reduction for PDD and DLB, 
except for the anterior cingulated and these findings support the hypothesis that these types 
of dementias are closely related and may be included in a unique spectrum (Yong et al., 
2007). These data are concordant with an innovative multitracer PET study on PDD, PD and 
DLB patients, which aims at highlighting the complex damage pattern at the base of these 
conditions (Klein et al., 2010). For the first time, a multidimensional approach was 
introduced to detect the complex issue of the neuropathological spectrum of Lewy Body 
dementias (see Fig. 1): besides FDG, 18fluorodopa (FDOPA) was used to study the 
dopaminergic system and N-11C-methyl-4-piperidyl acetate (MP4A) for the cholinergic one, 
aiming on identifying the different characteristics of these systems. The results did not 
succeed in the distinction between the two conditions of DLB and PDD, but allowed to 
identify the metabolic features of the observed neuronal systems. A dopaminergic deficit 
was showed in the amygdala, in the anterior cingulated and in the prefrontal cortex of 
patients compared to controls, whereas the analysis with MP4A highlighted a cholinergic 
deficit regarding the occipital cortex. As this cholinergic impairment did not regard PD 
patients without dementias, it seemed to be directly responsible for the development of 
dementia in addition to motor symptoms. In line with previous studies, FDG-PET 
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underlined a pattern of hypometabolism in correspondence of the cholinergic deficit, in the 
parieto-occipital brain regions. Taken together, in agreement with Klein and co-workers, 
these findings strengthen the concept that PDD and DLB represent two sides of the same 
coin in a continuum of Lewy Body Diseases.  
When facing the issue of the comparison between DLB and AD, the FDOPA PET represent 
an interesting way to distinguish between the two pathologies, since differently from DLB,  
AD is not affected by a dopaminergic dysfunction. Moreover, in this context also FDG-PET 
demonstrated effectiveness, revealing a decrease in the occipitotemporal metabolism of 
DLB, in accordance with  the visual processing problems that primarily DLB patients report 
(Gilman et al., 2005).  
The recent development of new PET ligands which can bind amyloid, such as the 
radiolabeled Pittsburgh compound B ([11C]PiB), opened new frontiers on the study of 
amyloid metabolism through PET (Tartaglia et al., 2011).  This aspect appears of importance 
in the study of DLB, since it was proven to be associated with amyloid deposition, as it 
happens in Alzheimer Disease (Brooks et al., 2009).  Previous literature suggested a similar 
pattern of amyloid high cortical deposition in AD and DLB (Backsai et al., 2007; Fodero-
Tavoletti et al., 2007; Maetzler et al., 2009), whereas  conflicting data are reported about the 
comparison between DLB and PDD. In fact, ([11C]PiB)-PET studies reported a significant 
increase in the amyloid load in DLB compared to PDD (Edison et al., 2008; Gomperts et al., 
2008), demonstrating the efficacy of this technique in the distinction between DLB and PDD. 
On the contrary, Foster and colleagues (Foster et al., 2010) showed that amyloid deposition 
did not allow differentation between different subtypes of Lewy Body associated disorders. 
In conclusion, the power of PET as well as SPECT analysis is represented by the modalities 
versatility, allowing the study of the different and complex neuropathological substrates of 
DLB which is not possible with other imaging modalities without tracers (Herholz et al., 
2007; Kemp et al., 2007). Nevertheless, the limits imposed by the use of radioactive isotope 
injection and high costs must be taken in consideration. 
2.2 MRI-based analyses techniques: Adding useful information to clinicians 
The importance of introducing advanced MR imaging techniques in the DLB diagnosis 
beside nuclear imaging methods is due to their capability to non-invasively detect early 
changes which could be potential biomarkers of the pathology. These MRI-based techniques 
can be used in large-scale studies thanks to the wide availability of MR scanners in clinics. 
MRI is a complex field including different approaches which permit the investigation of 
several aspects of brain structure and function. The clinical utility of structural 
neuroimaging with MRI for diagnosis and differential diagnosis of dementias is well-
established (Hentschel et al., 2005), however, conventional MRI in association with 
advanced methods of image processing (e.g. voxel-based morphometry) represent a 
powerful tool in tissue structure analysis. Moreover, the investigation of microstructural 
changes is permitted by DTI through the observation of water molecular displacements 
within tissues. Cerebral activity is also detectable by functional MRI (fMRI) techniques. In 
the following, we summarise the principal literature findings in  the study of DLB obtained 
using the above mentioned MRI approaches.  
2.2.1 Voxel Based Morphometry (VBM) 
The analysis with the technique of voxel based morphometry (VBM) on Magnetic Resonance 
images is one of the most widespread MRI-based approaches aimed at quantifying regional 
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differences across subjects in brain tissue volumes (see Box B for technical details). In the 
context of DLB, the use of VBM appears highly promising to investigate the pattern of gray 
and white matter (GM and WM) atrophy and the severity of the damage.  
Several literature studies used VBM to demonstrate the differences between DLB and PDD, 
and converged to reveal a pattern of more pronounced gray matter atrophy in DLB 
compared to PDD. These results appear in concordance with the ([11C]PiB)-PET findings of 
greater structural cortical changes in DLB related to amyloid burden (Edison et al., 2008; 
Gomperts et al., 2008). However, the distribution of this GM loss appears very 
heterogeneous among the different studies, and regards: the temporal (Beyer et al., 2007; 
Tam et al., 2005), parietal and occipital lobes (Beyer et al., 2007; Lee et al., 2010a), striatal 
areas (Lee et al., 2010a), right premotor areas, right inferior frontal lobe and right superior 
frontal gyrus (Sanchez-Castaneda et al., 2009). In a recent study, Sanchez-Castaneda and 
colleagues (Sanchez-Castaneda et al., 2010) found a different pattern of structural and 
functional correlations between the two dementias, in particular: decreases in volume in 
associative visual areas, left precuneus and inferior frontal lobe which correlates with visual 
hallucinations only in DLB. A possible explanation for these different results is the 
heterogeneity (e.g. disease duration, stage of dementia) amongst patients with PDD 
(patients who developed dementia early or later in the course of their illness) who are 
included in these small size studies. Moreover, the same pattern of atrophy measured in GM 
of DLB in respect to PDD was found also in WM by Lee and co-workers (Lee et al., 2010a). 
In their recent study, they demonstrated a significant decrease of the WM density in DLB, 
specifically in the bilateral occipital and left occipito-parietal areas. Moreover, they found 
that the atrophy level of GM and WM was similar in DLB patients, whereas WM damage 
was observed to a lesser severity in respect to GM loss in PDD. Taken together, these data 
may reflect the different nature of neuropathological aspects or potentially the different 
neuropathological stages regarding PDD and DLB. Further studies including a better clinical 
characterisation of patients (e.g. matching for age, dementia duration, and treatments) are 
needed to clarify the topic and delete this potential bias. 
As to the comparison between DLB and AD, the distinction in terms of cerebral atrophy 
between these two groups was not well defined. A few recent studies attempted to identify 
a pattern of cortical atrophy which could distinguish DLB patients from AD patients (Burton 
et al., 2009; Whitwell et al., 2007).  Whitwell et al. (Whitwell et al., 2007) highlighted a more 
severe cortical atrophy in AD compared to DLB patients regarding the medial temporal 
lobe, inferior temporal regions, the hippocampus and the temporoparietal cortex. Both 
groups revealed a pattern of damage in the midbrain and substantia innominata, although 
DLB patients showed a greater loss regarding the midbrain whereas AD regarding the 
substantia innominata. Thus, the specific pattern of cortical atrophy able to characterize DLB 
from AD was identified by Whitwell as a relatively focused loss in midbrain, substantia 
innominata and hypothalamus, with a sparing in hippocampus and temporal cortex. 
Changes in substantia innominata suggesting cholinergic impairment of DLB were also 
detected by Hanyu and co-workers (Hanyu et al., 2005; Hanyu et al., 2007). Furthermore, 
other studies found that the temporal (Beyer et al., 2007; Burton et al., 2009; Takahashi et al., 
2010) and frontal lobes (Beyer et al., 2007) are potentially interested by a more pronounced 
cortical loss in AD compared to DLB. In particular, Burton and colleagues (Burton et al., 
2009) showed that medial temporal lobe atrophy on MRI had an important role by 
distinguishing AD and DLB in pathologically confirmed cases.  
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Box B: Voxel Based Morphometry
Voxel-based morphometry (VBM) of structural MRI data is a well-established technique 
of group analysis which allows the comparison of regionally specific differences in the 
local concentration of gray matter between two groups of subjects on a voxel by voxel 
basis. Typically T1-weighted MRI scans enter the VBM analysis and the compared 
groups consist in a group of subjects with a disorder and an age-matched control group 
of healthy subjects, in order to highlight the features characterizing pathology, in terms 
of brain volumes. The technique of VBM has become increasingly popular over the last 
few years since it is relatively easy to use. It has also been applied to assess the patterns 
of grey and white matter loss regarding many different pathologies (Whitwell et al., 
2007). The importance of this approach is that it gives a comprehensive assessment of 
anatomical differences throughout the brain, without being biased to one particular 
structure (Ashburner and Friston, 2000), as it does not require any a priori assumptions 
concerning which structures to consider. This gives to the VBM a significant advantage 
over more traditional region of- interest (ROI) approaches, which involve the manual 
delineation of the structures of interest (Withwell et al., 2007), being therefore extremely 
operator-dependent and scarcely reproducible. 
The first step of the VBM analysis involves a spatial normalization of the images of all 
subjects to bring them to the same stereotactic space and perform voxel-wise comparisons. 
This is achieved by registering every image to one previously chosen template image, with 
the minimization of the residual sum of squared differences between them. Then, the gray 
matter is extracted from the normalized images by means of a segmentation of the 
different brain tissues from the images. The next step is the smoothing of gray matter 
images, in order to compensate for normalization errors and also to render the data more 
normally distributed, increasing thus the validity of parametric statistical tests. The 
accuracy of the gray matter segmentation step is essential in order to assure that the 
analysis of the proper structures of interest is performed. 
After that, the voxel-wise statistical analysis is performed with the aim of identifying 
positions in the brain where the gray matter concentration differs significantly between 
groups.  The General Linear Model (GLM) is used for the statistical analysis, allowing 
many different tests to be applied, as group comparisons and identification of regions of 
gray matter concentration that are related to particular covariates (e.g. pathology 
severity, age). The output from the method is a statistical parametric map showing 
regions where gray matter concentration differences between the compared groups 
appear statistically significant. 
Obviously the image pre-processing of the VBM analysis is required to be extremely 
accurate and rigorous to avoid errors of interpretation caused by misclassification of non-
brain voxels or voxels belonging to other  tissues, and to allow precise statistical analyses. 
One shortcoming of the VBM approach is in fact represented by the decrease in the 
sensitivity for the detection of group differences, associated with the variability among 
individuals both due to sample heterogeneity and to inaccuracies introduced with the 
image pre-processing. In addition, the smoothing step involves a trade off to be 
considered: while high levels of smoothing increase the ability of the technique to detect 
group differences by reducing the variance, excess smoothing diminishes the accuracy 
in the localization of changes. 
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In conclusion, the main findings of these studies can be summarised in the following key 
points: 1) the rate of cerebral cortical atrophy of DLB patients appears higher than PDD but 
at the same time lower than AD; 2) the medial temporal lobe structures are more preserved 
in both DLB and PDD in respect to AD (Beyer et al., 2007; Burton et al., 2009; Tam et al., 
2005; Whitwell et al., 2007); 3) DLB and PDD show greater changes in respect to AD in 
subcortical structures and this is due to dopaminergic system dysfunction (Hanyu et al., 
2007; Summerfield et al., 2005; Whitwell et al. 2007).     
2.2.2 Diffusion Tensor Imaging (DTI) 
Diffusion weighted and diffusion tensor imaging (DTI) could play an important role in the 
study of DLB, thanks to the unique capability of these techniques to investigate white matter 
microstructural damages, which could help in the definition of a characteristic 
neurodegenerative pattern and consequently in the differentiation of DLB patients from 
other dementias. White matter diffusion characteristics are primarily assessed by means of 
the computation of Mean Diffusivity (MD) and Fractional Anisotropy (FA) (see Box C for 
further technical details).  
Previous DTI studies on DLB were implemented initially with Regions Of Interest (ROI) based 
methods or voxel-based DTI and found diffusion abnormalities of the corpus callosum, 
pericallosal areas and the frontal, parietal, occipital and, less prominently, temporal white 
matter of patients compared with controls (Bozzali et al., 2005; Firbank et al., 2007a; Firbank et 
al., 2007b; Lee et al., 2010b). These findings in regions with a high prevalence of long 
connecting fibre tracts might suggest the presence of neurodegeneration involving associative 
cortices. Moreover, the selective involvement of parietal, frontal and occipital lobes might 
explain some of the clinical and neuropsychological features of DLB, providing a possible 
distinctive marker for this disease. The modest involvement of the temporal lobe, according to 
previously described VBM studies (Beyer et al., 2007; Burton et al., 2009; Tam et al., 2005; 
Takahashi et al., 2009; Whitwell et al., 2007), is consistent with the relative preservation of 
global neuropsychological measures and memory tasks in the early stage of DLB. More 
recently, Kantarci and colleagues (Kantarci et al., 2010) found increased MD in the amygdala 
and decreased FA in the inferior longitudinal fasciculus in DLB with respect to controls. 
Authors suggested that the former result could reflect the typical microvacuolation associated 
with LBs pathology in this structure, whereas the latter may be due to the presence of core 
symptoms of visual hallucinations. The encountered inferior longitudinal fasciculus damage in 
concordance with a tractography based study by Ota and colleagues (Ota et al., 2009) 
correlates with the pathology, as this bundle is responsible for visuospatial cognition and DLB 
is thought to involve an impairment of the visual association area. 
In the above mentioned study by Ota et al. (Ota et al., 2009) the findings were supported by the 
computation of eigenvalues (λ1, λ2, λ3), providing information about the magnitude of axial (λ1) 
and radial (λ2, λ3) diffusivity.  They found significantly lowered  λ2 and λ3 in the inferior 
longitudinal fasciculus of DLB patients in respect to healthy controls, however no difference was 
found in λ1. Furthermore, a recent study (Kiuchi et al., 2011) introduced the tractographic 
reconstruction of white matter fiber bundles not only for the study of DLB but also for the 
comparison with AD. The analysis was focused on the uncinate fasciculus, inferior fronto-
occipital fasciculus and inferior longitudinal fasciculus. Although no significant differences were 
seen between AD and DLB, some different features in the FA evaluation were found between 
each patient group and controls. In particular, significantly lowered FA values were found in 
bilateral uncinate fasciculus for both AD and DLB, and in bilateral inferior fronto-occipital  
www.intechopen.com
 




Box C: Diffusion weighted and Diffusion Tensor Imaging
Diffusion Weighted Imaging (DWI) is an advanced MRI technique providing invaluable 
information concerning tissue structure at a microscopic scale, thanks to the observation of 
the molecular diffusion. The image contrast in DWI depends, in fact, on the entity of water 
molecule diffusive displacements in tissues, and consequently on tissue microstructure. 
The basic principles of DWI, which has been an important area of research in the past 
decade, were introduced in the mid-1980s and combined conventional MR imaging 
principles with the use of sharp bipolar magnetic field gradient pulses in order to encode 
molecular diffusion effects in MR signal. The physical process of molecular diffusion, first 
formally described by Einstein in 1905, refers to the random motion of molecules, also 
called Brownian motion, which results from the thermal energy carried by these molecules 
(Beaulieu, 2002). The erratic motion of molecules in a homogeneous solution is statistically 
described by a displacement distribution, which represents the probability that a particular 
molecule travels a given distance in a given time interval, and is governed by the diffusion 
coefficient D.  In biological tissues, compared to solutions, the movement of molecules is 
hindered by macromolecules and cellular organelles and is also restricted by the 
confinement created by membranes. The macroscopic result is a decreased coefficient of 
diffusion, named apparent diffusion coefficient (ADC). In biological tissues with a highly 
anisotropic structure, such as white matter fibre bundles, diffusion is characterized by a 
specific directionality, since the peculiar structural arrangement of the medium limits 
molecular movement in some directions. To fully describe the diffusion process, it is thus 
necessary to investigate displacements of molecules not only along one direction, but 
along multiple dimensions. This is possible using Diffusion Tensor Imaging (DTI), which 
describes diffusion in the three-dimensional space using a tensor quantity D instead of a 
single coefficient. This provides a  detailed mathematical description of diffusion and 
allows to compute the principal direction of diffusion in every position of the explored 
tissue, as the principal eigenvector of the tensor. Moreover, from the tensor eigenvalues 
(λ1, λ2, λ3) computed in every voxel of the image, two useful scalar measures providing 
information about the diffusion features can be computed: the Mean Diffusivity (1) 
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(λ λ λ )
MD
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                                                        (1) 
indicating the diffusion magnitude, and the Fractional Anisotropy (2) 





(λ MD) (λ MD) (λ MD)3
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                        (2) 
providing an estimate of the degree of diffusion directionality. These metrics are 
commonly used to quantitatively assess diffusion features in healthy population and 
abnormalities in pathological tissues. Furthermore, DTI is at the base of the advanced 
technique of tractography (or fiber tracking), i.e. the virtual reconstruction of brain 
white matter tracts, starting from the assumption that the direction of major diffusion 
would indicate the overall orientation of the fibres in the brain.  This technique 
represents one of the most important area of current research and, in combination with 
fMRI, opens a window on the important issue of brain  connectivity. 
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Box D: BOLD signal and functional Magnetic Resonance Imaging
The functional Magnetic Resonance Imaging (fMRI) analysis provides invaluable 
information about the localization of neuronal activations related to a task or in a 
condition of rest, and for this reason is one of the most widely used method for brain 
mapping and measuring behaviour-related neural activity in the human brain. The 
development of functional techniques gives to MRI the ability to observe both the 
structures and also which structures participate in specific functions, gaining great 
power in the mapping of functional connectivity. Different fMRI techniques can be 
employed to measure the hemodynamic response, however fMRI based on blood-
oxygen level-dependent (BOLD) contrast has gained great success due to its high 
sensitivity and accessibility (Logothetis, 2002). This contrast was firstly described by 
Ogawa and colleagues in 1990 (Ogawa et al., 1990a; Ogawa et al., 1990b), with the 
introduction of a high resolution gradient-echo-pulse sequence accentuating the 
susceptibility effects of deoxygenated Hemoglobin (dHb) in the venous blood and 
obtaining therefore a signal dependent on the blood oxygen level. In fact, dHb owns a 
paramagnetic nature which induces a local alterations of the magnetic field in 
correspondence of the compartments containing dHb, and a consequent modification 
the T2* weighted MRI signal. The increase in regional CBF caused by a neuronal 
activation does not correspond to an increase in the oxygen consumption rate (Fox & 
Raichle, 1985), thus a decreased oxygen extraction fraction is observable and this results 
in a lower dHb content per volume unit in activated tissues (Logothetis, 2002). For this 
reason, activated areas will be characterized by a higher BOLD signal in the image. 
However, it was demonstrated that BOLD contrast is actually a complex type of 
response controlled by several parameters, depending therefore not only on blood 
oxygenation, but also on cerebral blood flux and volume (Ogawa et al. 1993; Ogawa et 
al., 1998; Van Zijl et al. 1998; Weisskoff et al. 1994). Although the exact relation between 
the blood oxygen-level dependent (BOLD) signal and the underlying neural activity 
appears difficult to explicate, fMRI experiments allow to observe which brain areas 
activate in relation to the performance of a particular task. Patients are required to 
perform a specific task during the MRI acquisition, expecting the activation of specific 
corresponding brain areas during the task. This information is useful both in healthy 
subjects, to map the normal cerebral functions, and in presence of diseases, aiming on 
underlying possible changes of functionality in damaged brains. Moreover, fMRI opens 
a window on the complicated issue of neuronal connectivity, allowing the observation 
of functional connections between different areas in the brain, and of neuronal plasticity, 
i.e. the capability of the brain functions to change and adapt to external inputs, during 
life or in presence of pathologies. Recently, the fMRI analysis in a condition of resting 
(so called resting state condition) is gaining more attention in the current research, 
aiming on exploring the activated areas and their connections during rest. In respect to 
other techniques to map brain functional activity, some aspects characterizing fMRI can 
be listed as advantages of this technique: firstly, the signal does not require injections of 
radioactive isotopes as it happens for positron emission tomography (PET); the in-plane 
resolution of functional images could be less than 1 mm; furthermore, the total 
acquisition time can be very short, depending on the paradigm to perform. 
www.intechopen.com
 
Neuroimaging Findings in Dementia with Lewy Body: A Review 
 
327 
fasciculus and left inferior longitudinal fasciculus for DLB with respect to controls, 
suggesting that DLB exhibited modifications in visual-related WM tractcs.  
From all these studies, we can argue that tractographic reconstruction proved to be helpful 
for a better understanding of WM connectivity in DLB patients and in particular for the 
detection of visual related damages in this dementia. 
2.2.3 Functional Magnetic Resonance Imaging (fMRI) 
The most diffuse neuroimaging techniques for the evaluation of brain activity and 
function in DLB are undoubtedly the above mentioned PET and SPECT. Functional 
investigations with fMRI (details in Box D) in DLB are still developing and currently 
appears less widespread than nuclear imaging studies. A unique task-related fMRI study 
(Sauer et al., 2006) was conducted and investigated the pattern of activations in DLB and 
AD during visual colour, face and motor stimuli. A significantly greater activation of DLB 
compared to AD, independent on task performance, age or cognitive score, was found in 
the superior temporal sulcus during the motor task. Instead, performance-dependent 
differences were found in the activation patterns related to the motor and face task, in 
which the activity appeared higher for AD compared to DLB, and in the default mode 
network pattern, in which the effect was greater for AD and DLB with respect to controls. 
Authors concluded thus that fMRI can be reliably used for the detection of functional 
activity distribution patterns in these two conditions. However, the role of fMRI remains 
unclear in the study of those patients, as the significance of the found results are not 
completely understood. Further studies combining anatomical MRI, DTI, and resting state 
fMRI are needed, in order to verify the hypothesis that structural subcortico-cortical 
connections may provide integral routes for communication between cortical resting state 
networks, and that changes in the integrity of these connections have a role in this 
dementia. 
3. Conclusion  
In this chapter, we reviewed the literature concerning the study of DLB through 
imaging techniques. We have shown that the use of neuro-imaging methods could 
noticeably improve the differential diagnosis of DLB when several doubts exist. To 
solve this problem, the nuclear imaging methods (PET/SPECT) play nowadays the 
principal role (O’Brien et al., 2007). However, MRI techniques revealed interesting 
results and although they are now limited to the research field, except for the 
assessment of medial temporal lobe preservation with structural MRI, they seem to be a 
promising measure for detecting early and potentially preclinical DLB changes and for 
the validation of surrogate markers to be applied in longitudinal studies and 
pharmacological trials (von Gunten & Meuli, 2009; Watson et al., 2009). We think that 
the combination of different MRI methods may contribute to a better understanding of 
this often misdiagnosed pathology.  
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